A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This 2 arm crossover study will evaluate patient reported preference for either once monthly
Boniva (150mg p.o.) or once weekly risedronate (35mg p.o.). Patients with post-menopausal
osteoporosis will be randomized to receive Boniva for 3 calendar months or risedronate for 12
weeks; they will then cross over to receive the alternative treatment for a further 12
weeks/3 months. The anticipated time on study treatment is 3-12 months, and the target sample
size is 100-500 individuals.